Research article summary (published 30 Dec 2003):

New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential.

Full Abstract

New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one immediate release and four longer-acting preparations) that have recently become available for the treatment of ADHD. While the therapeutic potential of immediate-release enantiomers of methylphenidate has not yet been clinically realised, new long-acting formulations of stimulants have changed the standard of care for children, adolescents and adults with ADHD. The longer duration of action of these once-daily compounds, and the consequent expansion of the duration of daily ADHD coverage afforded by them, has introduced the realistic possibility of reducing the overall daily burden of ADHD on affected individuals. Although more expensive, these new stimulant formulations are easier for patients to use than older stimulants, more resistant to abuse and misuse, and allow for increased privacy of ADHD treatment at school or work.

Author information

Author/s: Connor, Daniel F (DF); Steingard, Ronald J (RJ);

Affiliation: Department of Psychiatry, Division of Child and Adolescent Psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA. daniel.connor(-atsign-)umassmed.edu

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

Journal: CNS drugs (CNS Drugs), published in New Zealand. (Language: eng)

Reference: 2004-; vol 18 (issue 14) : pp 1011-30

Dates: Created 2004/12/08; Completed 2004/12/29; Revised 2009/11/03;

PMID: 15584770, status: MEDLINE (last retrieved date: 11/3/2009)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MeSH Headings (categories) shown below.

Attention Deficit Disorder with Hyperactivity - drug therapy; psychology Central Nervous System Stimulants - chemistry; pharmacokinetics; therapeutic use Child Clinical Trials as Topic

Delayed-Action Preparations Humans Methylphenidate - chemistry; pharmacokinetics; therapeutic use Stereoisomerism

Note: Bold headings indicate primary MeSH headings or qualifiers.

Associated Chemicals: Central Nervous System Stimulants (0) ; Delayed-Action Preparations (0) ; Methylphenidate (113-45-1)

Related articles

These are the most related articles currently in our database:

• Pharmacokinetics and clinical effectiveness of methylphenidate. 29 Nov 1999
• Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. 27 Mar 2007
• [Attention deficit hyperactivity disorder in children] 27 Feb 2002
• A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. 30 Oct 2004
• Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. 8 Mar 2002
• Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. 29 Jun 2006
• Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. 30 Jul 2008
• Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. 10 Jan 2005
• Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. 30 Dec 2003
• An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. 30 Dec 2007

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a larger map of 100+ related articles.